Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Raper, S. E., Chirmule, N., Lee, F. S., Wivel, N. A., Bagg, A., Gao, G.-P., Wilson, J. M., & Batshaw, M. L. (2003) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.08.016 · Cited by 1,498 · cited 1×
“First, AAV vectors had never been administered to liver in human subjects before, and the only death in a gene therapy trial at that point had been in a trial in which adenoviral vectors were administered to the liver in subjects with OTC deficienc”
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Convection-enhanced delivery of macromolecules in the brain.
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., & Oldfield, E. H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2076 · Cited by 1,415
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176 · cited 1×
“This may be particularly challenging in settings where the patient population is small, the natural history of the disease progression is ill defined and/or biomarkers to monitor therapeutic efficac”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationGene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Self-citationLeber congenital amaurosis: Genes, proteins and disease mechanisms
den Hollander, A. I., Roepman, R., Koenekoop, R. K., & Cremers, F. P. M. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.003 · Cited by 811
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Principles and Practice of Medical Genetics
Pembrey, M. (1984) · Archives of Disease in Childhood · doi:10.1136/adc.59.2.192 · Cited by 776
Current prospects for RNA interference-based therapies
Davidson, B. L., & McCray, P. B. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2968 · Cited by 761
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Self-citationNucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Harper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
AAV vector integration sites in mouse hepatocellular carcinoma
Donsante, A., Miller, D. G., Li, Y., Vogler, C., Brunt, E. M., Russell, D. W., & Sands, M. S. (2007) · Science · doi:10.1126/science.1142658 · Cited by 662 · cited 1×
“)? And third, what is the risk of vector integration, and resulting insertional mutagenesis, with this predominantly non-integrating vector at the doses currently being investigated in live”
BackgroundDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593 · cited 1×
“As well as this unmet need, a number of other factors make haemophilia an attractive target for gene transfer to liver: the therapeutic window is wide (increasing factor IX levels to >2% of normal levels will improve phenotype, and levels up to 150% are still within the normal range); end points are easy to measure; a…”
BackgroundSelf-citationQuantitative analysis of the packaging capacity of recombinant adeno-associated virus
Dong, J.-Y., Fan, P.-D., & Frizzell, R. A. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.17-2101 · Cited by 583
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Self-citationSimonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., Rossi, S., Marshall, K., Banfi, S., Surace, E. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.277 · Cited by 553
Self-citationMcCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Adeno-associated virus vectors can be efficiently produced without helper virus
Matsushita, T., Elliger, S., Elliger, C., Podsakoff, G., Villarreal, L., Kurtzman, G., Iwaki, Y., & Colosi, P. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300680 · Cited by 500
Acland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477 · cited 1×
“Preclinical studies in animal models had clearly established that restoration of vision was most successful in younger animal”
BackgroundInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466 · cited 1×
“Subsequent work demonstrated that expression of a transgene from an AAV vector in the liver promotes tolerance to the transgene produc”
BackgroundSelf-citationJaski, B. E., Jessup, M. L., Mancini, D. M., Cappola, T. P., Pauly, D. F., Greenberg, B., Borow, K., Dittrich, H., Zsebo, K. M., & Hajjar, R. J. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.01.013 · Cited by 457
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
Christine, C. W., Starr, P. A., Larson, P. S., Eberling, J. L., Jagust, W. J., Hawkins, R. A., VanBrocklin, H. F., Wright, J. F., Bankiewicz, K. S., & Aminoff, M. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c29356 · Cited by 445
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Cearley, C. N., & Wolfe, J. H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.015 · Cited by 409
Aspartoacylase deficiency and N‐acetylaspartic aciduria in patients with canavan disease
Matalon, R., Michals, K., Sebesta, D., Deanching, M., Gashkoff, P., Casanova, J., Optiz, J. M., & Reynolds, J. F. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320290234 · Cited by 404
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
AAV serotype 2 vectors preferentially integrate into active genes in mice
Nakai, H., Montini, E., Fuess, S., Storm, T. A., Grompe, M., & Kay, M. A. (2003) · Nature Genetics · doi:10.1038/ng1179 · Cited by 392
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
Eberling, J. L., Jagust, W. J., Christine, C. W., Starr, P., Larson, P., Bankiewicz, K. S., & Aminoff, M. J. (2008) · Neurology · doi:10.1212/01.wnl.0000312381.29287.ff · Cited by 370
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339 · cited 1×
“was based on robust preclinical results in two haemophilia B dog model”
MethodSelf-citationHaemophilia prophylaxis in young patients–a long‐term follow‐up
LÖFQVIST, T., NILSSON, I. M., BERNTORP, E., & PETTERSSON, H. (1997) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1997.130135000.x · Cited by 332 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundJiang, H., Couto, L. B., Patarroyo-White, S., Liu, T., Nagy, D., Vargas, J. A., Zhou, S., Scallan, C. D., Sommer, J., Vijay, S., et al. (2006) · Blood · doi:10.1182/blood-2006-04-017913 · Cited by 330
Self-citationBrantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904514106 · Cited by 327
Binder, D. K., Rau, G. M., & Starr, P. A. (2005) · Neurosurgery · doi:10.1227/01.neu.0000156473.57196.7e · Cited by 296
Mingozzi, F., Meulenberg, J. J., Hui, D. J., Basner-Tschakarjan, E., Hasbrouck, N. C., Edmonson, S. A., Hutnick, N. A., Betts, M. R., Kastelein, J. J., Stroes, E. S., et al. (2009) · Blood · doi:10.1182/blood-2008-07-167510 · Cited by 295 · cited 1×
“Published data suggest that T cell responses directed against the AAV capsid are dose-dependent, with an increase in the frequency of circulating reactive T cells in PBMC samples and in the frequency of reactive subjects at higher vector dose”
BackgroundSelf-citationA Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B
Lin, H.-F., Maeda, N., Smithies, O., Straight, D. L., & Stafford, D. W. (1997) · Blood · doi:10.1182/blood.v90.10.3962 · Cited by 290
Principles and Practice of Medical Genetics.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-817_2 · Cited by 290
Moss, R. B., Milla, C., Colombo, J., Accurso, F., Zeitlin, P. L., Clancy, J. P., Spencer, L. T., Pilewski, J., Waltz, D. A., Dorkin, H. L., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.022 · Cited by 277
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A. M., Conrad, C. K., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128577 · Cited by 266
Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255
Mingozzi, F., Hasbrouck, N. C., Basner-Tschakarjan, E., Edmonson, S. A., Hui, D. J., Sabatino, D. E., Zhou, S., Wright, J. F., Jiang, H., Pierce, G. F., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080093 · Cited by 254
Self-citationMendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248
Immune responses to AAV in a phase I study for Canavan disease
McPhee, S. W. J., Janson, C. G., Li, C., Samulski, R. J., Camp, A. S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., et al. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.885 · Cited by 241
The Burden of Genetic Disease on Inpatient Care in a Children’s Hospital
McCandless, S. E., Brunger, J. W., & Cassidy, S. B. (2004) · The American Journal of Human Genetics · doi:10.1086/381053 · Cited by 240 · cited 1×
“jpg"/> Inherited diseases account for a substantial burden of disease, including up to 70% of all admissions to children's hospital”
BackgroundAitken, M. L., Moss, R. B., Waltz, D. A., Dovey, M. E., Tonelli, M. R., McNamara, S. C., Gibson, R. L., Ramsey, B. W., Carter, B. J., & Reynolds, T. C. (2001) · Human Gene Therapy · doi:10.1089/104303401753153956 · Cited by 239
Assessing the potential for AAV vector genotoxicity in a murine model
Li, H., Malani, N., Hamilton, S. R., Schlachterman, A., Bussadori, G., Edmonson, S. E., Shah, R., Arruda, V. R., Mingozzi, F., Fraser Wright, J., et al. (2011) · Blood · doi:10.1182/blood-2010-08-302729 · Cited by 236
Self-citationEfficient and persistent gene transfer of AAV-CFTR in maxillary sinus
Wagner, J. A., Reynolds, T., Moran, M. L., Moss, R. B., Wine, J. J., Flotte, T. R., & Gardner, P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)77740-0 · Cited by 225
Yan, Z., Zak, R., Luxton, G. W. G., Ritchie, T. C., Bantel-Schaal, U., & Engelhardt, J. F. (2002) · Journal of Virology · doi:10.1128/jvi.76.5.2043-2053.2002 · Cited by 222
Powell, J. S., Ragni, M. V., White, G. C., Lusher, J. M., Hillman-Wiseman, C., Moon, T. E., Cole, V., Ramanathan-Girish, S., Roehl, H., Sajjadi, N., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0167 · Cited by 217
Limb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins
Mendell, J. R., Rodino‐Klapac, L. R., Rosales‐Quintero, X., Kota, J., Coley, B. D., Galloway, G., Craenen, J. M., Lewis, S., Malik, V., Shilling, C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21732 · Cited by 214
Follenzi, A., Battaglia, M., Lombardo, A., Annoni, A., Roncarolo, M. G., & Naldini, L. (2004) · Blood · doi:10.1182/blood-2003-09-3217 · Cited by 212 · cited 1×
“This result has been confirmed using other vectors, including lentiviral vector”
ResultWagner, J. A., Messner, A. H., Moran, M. L., Daifuku, R., Kouyama, K., Desch, J. K., Manley, S., Norbash, A. M., Conrad, C. K., Friborg, S., et al. (1999) · The Laryngoscope · doi:10.1097/00005537-199902000-00017 · Cited by 210
Stroes, E. S., Nierman, M. C., Meulenberg, J. J., Franssen, R., Twisk, J., Henny, C. P., Maas, M. M., Zwinderman, A. H., Ross, C., Aronica, E., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.175620 · Cited by 209
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Jiang, H., Pierce, G. F., Ozelo, M. C., de Paula, E. V., Vargas, J. A., Smith, P., Sommer, J., Luk, A., Manno, C. S., High, K. A., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.004 · Cited by 207
Self-citationManufacturing and characterizing AAV-based vectors for use in clinical studies
Wright, J. F. (2008) · Gene Therapy · doi:10.1038/gt.2008.65 · Cited by 205
Vision 1 Year after Gene Therapy for Leber's Congenital Amaurosis
Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, S. L., Windsor, E. A. M., Conlon, T. J., Sumaroka, A., Roman, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0903652 · Cited by 199
Fu, H., DiRosario, J., Killedar, S., Zaraspe, K., & McCarty, D. M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.34 · Cited by 197
Pien, G. C., Basner-Tschakarjan, E., Hui, D. J., Mentlik, A. N., Finn, J. D., Hasbrouck, N. C., Zhou, S., Murphy, S. L., Maus, M. V., Mingozzi, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36891 · Cited by 192 · cited 1×
“By contrast, in vitro models of AAV antigen presentation and cytotoxic T lymphocyte-mediated clearance of transduced human cells have been more reliable tools for the study of AAV capsid antigen processing and presentatio”
MethodSelf-citationKang, E. M., Choi, U., Theobald, N., Linton, G., Long Priel, D. A., Kuhns, D., & Malech, H. L. (2010) · Blood · doi:10.1182/blood-2009-05-222760 · Cited by 190
Canine hemophilia B resulting from a point mutation with unusual consequences.
Evans, J. P., Brinkhous, K. M., Brayer, G. D., Reisner, H. M., & High, K. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10095 · Cited by 189
Self-citationGray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185
Brantly, M. L., Spencer, L. T., Humphries, M., Conlon, T. J., Spencer, C. T., Poirier, A., Garlington, W., Baker, D., Song, S., Berns, K. I., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1177 · Cited by 177
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173
Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170
Franco, L. M., Sun, B., Yang, X., Bird, A., Zhang, H., Schneider, A., Brown, T., Young, S. P., Clay, T. M., Amalfitano, A., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.04.024 · Cited by 169
Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy
Chen, Y. H., Chang, M., & Davidson, B. L. (2009) · Nature Medicine · doi:10.1038/nm.2025 · Cited by 168 · cited 1×
“Chen and colleagues took advantage of disease-specific changes in the brain endothelium in lysosomal storage disorders to redirect the tropism of AAV vector”
BackgroundA factor IX-deficient mouse model for hemophilia B gene therapy
Wang, L., Zoppè, M., Hackeng, T. M., Griffin, J. H., Lee, K.-F., & Verma, I. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11563 · Cited by 164 · cited 1×
“As well as this unmet need, a number of other factors make haemophilia an attractive target for gene transfer to liver: the therapeutic window is wide (increasing factor IX levels to >2% of normal levels will improve phenotype, and levels up to 150% are still within the normal range); end points are easy to measure; a…”
BackgroundBrooks, A. I., Stein, C. S., Hughes, S. M., Heth, J., McCray, P. M., Sauter, S. L., Johnston, J. C., Cory-Slechta, D. A., Federoff, H. J., & Davidson, B. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082011999 · Cited by 160 · cited 1×
“Although a number of studies suggest that we do not yet fully grasp the level of plasticity of the CN”
BackgroundChromosomal effects of adeno-associated virus vector integration
Miller, D. G., Rutledge, E. A., & Russell, D. W. (2002) · Nature Genetics · doi:10.1038/ng824 · Cited by 155
Arruda, V. R., Fields, P. A., Milner, R., Wainwright, L., De Miguel, M. P., Donovan, P. J., Herzog, R. W., Nichols, T. C., Biegel, J. A., Razavi, M., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0491 · Cited by 154
Self-citationArruda, V. R., Schuettrumpf, J., Herzog, R. W., Nichols, T. C., Robinson, N., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L. B., & High, K. A. (2004) · Blood · doi:10.1182/blood-2003-05-1446 · Cited by 150 · cited 1×
“, studies in haemophilic dogs demonstrated that the approach was associated in outbred, immunocompetent large animals with the development of inhibitory antibodie”
BackgroundSelf-citationInhibition of human natural cytotoxicity by macromolecular antiproteases.
Hudig, D., Haverty, T., Fulcher, C., Redelman, D., & Mendelsohn, J. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.4.1569 · Cited by 147
Herzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., & High, K. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128513 · Cited by 147 · cited 1×
“Based on studies in haemophilic dogs, it was clear that the formation of antibodies to the transgene product, factor IX, was a risk with this delivery metho”
BackgroundSelf-citationJung, S.-C., Han, I. P., Limaye, A., Xu, R., Gelderman, M. P., Zerfas, P., Tirumalai, K., Murray, G. J., During, M. J., Brady, R. O., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051634498 · Cited by 143
Ziegler, R. J., Lonning, S. M., Armentano, D., Li, C., Souza, D. W., Cherry, M., Ford, C., Barbon, C. M., Desnick, R. J., Gao, G., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.015 · Cited by 141
Expression of human factor IX in mice after injection of genetically modified myoblasts.
Yao, S. N., & Kurachi, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3357 · Cited by 138 · cited 1×
“As well as this unmet need, a number of other factors make haemophilia an attractive target for gene transfer to liver: the therapeutic window is wide (increasing factor IX levels to >2% of normal levels will improve phenotype, and levels up to 150% are still within the normal range); end points are easy to measure; a…”
BackgroundEfficient gene therapy-based method for the delivery of therapeutics to primate cortex
Kells, A. P., Hadaczek, P., Yin, D., Bringas, J., Varenika, V., Forsayeth, J., & Bankiewicz, K. S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810682106 · Cited by 134
Daly, T., Ohlemiller, K. K., Roberts, M., Vogler, C., & Sands, M. S. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301420 · Cited by 133
Calcineurin and human heart failure
Lim, H. W., & Molkentin, J. D. (1999) · Nature Medicine · doi:10.1038/6430 · Cited by 131
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material
Lock, M., McGorray, S., Auricchio, A., Ayuso, E., Beecham, E. J., Blouin-Tavel, V., Bosch, F., Bose, M., Byrne, B. J., Caton, T., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.223 · Cited by 131
Gaudet, D., de Wal, J., Tremblay, K., Déry, S., van Deventer, S. J. H., Freidig, A. P., Brisson, D., & Méthot, J. (2010) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2010.03.004 · Cited by 130 · cited 1×
“Indeed, the first licensing application for a gene therapy drug for a genetic disease has now been file”
BackgroundThe Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Favre, D., Provost, N., Blouin, V., Blancho, G., Chérel, Y., Salvetti, A., & Moullier, P. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0494 · Cited by 122
Mandel, R. J. (2010) · PubMed · Cited by 121
Liu, G., Martins, I., Wemmie, J. A., Chiorini, J. A., & Davidson, B. L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2936-05.2005 · Cited by 120
Walter, J., You, Q., Hagstrom, J. N., Sands, M., & High, K. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.3056 · Cited by 120
Self-citationArruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P., Chen, Y., Franck, H. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 117
Self-citationFinn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115
Self-citationMEASE, P. J., WEI, N., FUDMAN, E. J., KIVITZ, A. J., SCHECHTMAN, J., TRAPP, R. G., HOBBS, K. F., GREENWALD, M., HOU, A., BOOKBINDER, S. A., et al. (2010) · The Journal of Rheumatology · doi:10.3899/jrheum.090817 · Cited by 114
Wang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113
Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles-Davis, W., Edmonson, S., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 108
Self-citationSustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector
Scallan, C. D., Lillicrap, D., Jiang, H., Qian, X., Patarroyo-White, S. L., Parker, A. E., Liu, T., Vargas, J., Nagy, D., Powell, S. K., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0292 · Cited by 103
Mease, P. J., Hobbs, K., Chalmers, A., El-Gabalawy, H. S., BOOKMAN, A. A. M., Keystone, E. C., Fürst, D. E., Anklesaria, P. N., & Heald, A. E. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.089375 · Cited by 101
Lebherz, C., Gao, G., Louboutin, J., Millar, J., Rader, D., & Wilson, J. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.554 · Cited by 99
Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery
Cardone, M., Polito, V. A., Pepe, S., Mann, L., D'Azzo, A., Auricchio, A., Ballabio, A., & Cosma, M. P. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl038 · Cited by 99
Watson, G., Bastacky, J., Belichenko, P. V., Buddhikot, M., Jungles, S., Vellard, M. C., Mobley, W. C., & Kakkis, E. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302735 · Cited by 97
Rodino-Klapac, L. R., Montgomery, C. L., Bremer, W. G., Shontz, K. M., Malik, V., Davis, N., Sprinkle, S., Campbell, K. J., Sahenk, Z., Clark, K. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.254 · Cited by 97
Brunetti-Pierri, N., Stapleton, G. E., Law, M., Breinholt, J., Palmer, D. J., Zuo, Y., Grove, N. C., Finegold, M. J., Rice, K., Beaudet, A. L., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.257 · Cited by 92
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88
Self-citationSeppen, J., Bakker, C., de Jong, B., Kunne, C., van den Oever, K., Vandenberghe, K., de Waart, R., Twisk, J., & Bosma, P. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.014 · Cited by 87
Li, C., Hirsch, M., Asokan, A., Zeithaml, B., Ma, H., Kafri, T., & Samulski, R. J. (2007) · Journal of Virology · doi:10.1128/jvi.00529-07 · Cited by 87 · cited 1×
“These differences may account for the several animal studie”
BackgroundNewborn Screening for Treatable Genetic Conditions: Past, Present and Future
Hiraki, S. C., & Green, N. (2010) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2010.01.002 · Cited by 87 · cited 1×
“Rapid advances in DNA diagnostics are expanding the breadth of newborn screenin”
BackgroundA deletion mutation causes hemophilia B in Lhasa Apso dogs
Mauser, A., Whitlark, J., Whitney, K., & Lothrop, C. J. (1996) · Blood · doi:10.1182/blood.v88.9.3451.bloodjournal8893451 · Cited by 82
Ross, C. J. D., Twisk, J., Bakker, A. C., Miao, F., Verbart, D., Rip, J., Godbey, T., Dijkhuizen, P., Hermens, W. T. J. M. C., Kastelein, J. J. P., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.487 · Cited by 82
Cabrera-Salazar, M. A., Roskelley, E. M., Bu, J., Hodges, B. L., Yew, N., Dodge, J. C., Shihabuddin, L. S., Sohar, I., Sleat, D. E., Scheule, R. K., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300249 · Cited by 82
Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice
Gao, J., Chen, J., De Domenico, I., Koeller, D. M., Harding, C. O., Fleming, R. E., Koeberl, D. D., & Enns, C. A. (2010) · Blood · doi:10.1182/blood-2009-09-245209 · Cited by 81
Koeberl, D. D., Sun, B., Damodaran, T. V., Brown, T. T., Millington, D. S., Benjamin, D. K., Bird, A., Schneider, A., Hillman, S. L., Jackson, M., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302774 · Cited by 80
Cellular immune response to cryptic epitopes during therapeutic gene transfer
Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902269106 · Cited by 79
Su, L. T., Gopal, K., Wang, Z., Yin, X., Nelson, A., Kozyak, B. W., Burkman, J. M., Mitchell, M. A., Low, D. W., Bridges, C. R., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.534008 · Cited by 79
Lu, Y., Choi, Y., Campbell‐Thompson, M., Li, C., Tang, Q., Crawford, J. M., Flotte, T. R., & Song, S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.896 · Cited by 76
Moscioni, D., Morizono, H., McCarter, R. J., Stern, A., Cabrera-Luque, J., Hoang, A., Sanmiguel, J., Wu, D., Bell, P., Gao, G.-P., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.009 · Cited by 75
Leber Hereditary Optic Neuropathy Gene Therapy Clinical Trial Recruitment: Year 1
Lam, B. L. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.201 · Cited by 73
Schüttrumpf, J., Liu, J., Couto, L. B., Addya, K., Leonard, D. G. B., Zhen, Z., Summer, J., & Arruda, V. R. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.002 · Cited by 73
Investigation of the Cause of Death in a Gene-Therapy Trial
Frank, K. M., Hogarth, D. K., Miller, J. L., Mandal, S., Mease, P. J., Samulski, R. J., Weisgerber, G. A., & Hart, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0801066 · Cited by 72
Current Status of Gene Therapy for Inherited Lung Diseases
Driskell, R. A., & Engelhardt, J. F. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142426 · Cited by 70
Xu, L., Nichols, T. C., Sarkar, R., McCorquodale, S., Bellinger, D. A., & Ponder, K. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409249102 · Cited by 70
McEachern, K. A., Nietupski, J. B., Chuang, W., Armentano, D., Johnson, J., Hutto, E., Grabowski, G. A., Cheng, S. H., & Marshall, J. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.901 · Cited by 68
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Haurigot, V., Mingozzi, F., Buchlis, G., Hui, D. J., Chen, Y., Basner-Tschakarjan, E., Arruda, V. R., Radu, A., Franck, H. G., Wright, J. F., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.73 · Cited by 66
Self-citationDing, Z., Harding, C. O., Rebuffat, A., Elzaouk, L., Wolff, J. A., & Thöny, B. (2008) · Molecular Therapy · doi:10.1038/mt.2008.17 · Cited by 64
Clinical Gene Transfer Studies for Hemophilia A
Chuah, M., Collen, D., & VandenDriessche, T. (2004) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2004-825638 · Cited by 63
Toromanoff, A., Adjali, O., Larcher, T., Hill, M., Guigand, L., Chenuaud, P., Deschamps, J.-Y., Gauthier, O., Blancho, G., Vanhove, B., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.251 · Cited by 61
Reversal of Type 1 Diabetes by Engineering a Glucose Sensor in Skeletal Muscle
Mas, A., Montané, J., Anguela, X. M., Muñoz, S., Douar, A. M., Riu, E., Otaegui, P., & Bosch, F. (2006) · Diabetes · doi:10.2337/db05-1615 · Cited by 60
Comprehensive care for haemophilia around the world
Evatt, B. L., Black, C., Bátorová, A., Street, A., & Srivastava, A. (2004) · Haemophilia · doi:10.1111/j.1365-2516.2004.01010.x · Cited by 58 · cited 1×
“For the poorest, the disease remains lethal in childhood or adolescenc”
BackgroundPalfi, A., Millington-Ward, S., Chadderton, N., O'Reilly, M., Goldmann, T., Humphries, M. M., Li, T., Wolfrum, U., Humphries, P., Kenna, P. F., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.119 · Cited by 56
Conlon, T. J., Cossette, T., Erger, K., Choi, Y.-K., Clarke, T., Scott-Jorgensen, M., Song, S., Campbell-Thompson, M., Crawford, J., & Flotte, T. R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.016 · Cited by 56
Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus
Anand, V., Barral, D. C., Zeng, Y., Brunsmann, F., Maguire, A. M., Seabra, M. C., & Bennett, J. (2003) · Vision Research · doi:10.1016/s0042-6989(02)00389-9 · Cited by 56 · cited 1×
“However, demonstration of proof-of-concept in this disease has laid the groundwork for trials for a host of more common inherited retinal degenerative disorders, such as Leber's hereditary optic neuropathy, choroideraemi”
BackgroundFan, Z., Kocis, K., Valley, R., Howard, J. F., Chopra, M., An, H., Lin, W., Muenzer, J., & Powers, W. (2012) · Molecular Therapy · doi:10.1038/mt.2011.137 · Cited by 55
Carrillo-Carrasco, N., Chandler, R. J., Chandrasekaran, S., & Venditti, C. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.008 · Cited by 54
Le, M., Okuyama, T., Cai, S.-R., Kennedy, S. C., Bowling, W. M., Flye, M. W., & Ponder, K. P. (1997) · Blood · doi:10.1182/blood.v89.4.1254 · Cited by 54
Principles and practice of medical genetics (2nd edn)
Ponder, B. A. J. (1991) · Trends in Genetics · doi:10.1016/0168-9525(91)90372-w · Cited by 51
Hanley, J. P., JARVIS, L. M., Andrews, J., Dennis, R., Lee, R. E., Peter Simmonds, K., Piris, J., Hayes, P. C., & Ludlam, C. A. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.6192064.x · Cited by 49
Chandler, R. J., Chandrasekaran, S., Carrillo, N., Senac, J. S., Hofherr, S. E., Barry, M. A., & Venditti, C. P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.164 · Cited by 47
Velazquez, V. M., Bowen, D. G., & Walker, C. M. (2009) · Blood · doi:10.1182/blood-2008-01-131375 · Cited by 46
Lozier, J. N., Thompson, A. R., Hu, P.-C., Read, M. S., Brinkhous, K. M., High, K. A., & Curiel, D. T. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.3-313 · Cited by 44
Self-citationHost and Vector-dependent Effects on the Risk of Germline Transmission of AAV Vectors
Favaro, P., Downey, H. D., Zhou, J. S., Wright, J. F., Hauck, B., Mingozzi, F., High, K. A., & Arruda, V. R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.56 · Cited by 40
Self-citationXu, L., Mei, M., Haskins, M. E., Nichols, T. C., O’Donnell, P., Cullen, K., Dillow, A. M., Bellinger, D. A., & Ponder, K. P. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2006.09.010 · Cited by 37
Manufacturing and Regulatory Strategies for Clinical AAV2-hRPE65
Fraser Wright, J., Wellman, J., & High, K. (2010) · Current Gene Therapy · doi:10.2174/156652310793180715 · Cited by 36
Self-citationHemophilia gene therapy: a Holy Grail found.
Ponder, K. (2011) · Molecular Therapy · doi:10.1038/mt.2011.13 · Cited by 33
Nathwani, A., Tuddenham, E., Rosales, C., McIntosh, J., Riddell, A., Rustagi, P., Glader, B., Kay, M., Allay, J., Coleman, J., et al. (2010) · Blood · doi:10.1182/blood.v116.21.248.248 · Cited by 24
Self-citationNeuronal ceroid lipofuscinoses
Mole, S. (2001) · European Journal of Paediatric Neurology · doi:10.1053/ejpn.2001.0514 · Cited by 24
(2006) · The Journal of Gene Medicine · doi:10.1002/jgm.991 · Cited by 21
(1999) · Nature Medicine · doi:10.1038/6429 · Cited by 17
Recombinant adeno-associated virus mediated gene transfer in a mouse model for homocystinuria
Park, E. S., Oh, H.-J., Kruger, W. D., Jung, S., & Lee, J. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.77 · Cited by 11
328. Safety and Feasibility of Transvenous Limb Perfusion with Saline in Human Muscular Dystrophy
(2010) · Molecular Therapy · doi:10.1016/s1525-0016(16)37769-3 · Cited by 2
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
“For this purpose, adeno-associated virus (AAV) vectors are attractive vehicles 10 because of their low immunogenic potential, reduced oncogenic risk from host-genome integration 11 , and broad-range of serotype specificity 12–15 .”
BackgroundAdeno-Associated Virus (AAV) as a Vector for Gene Therapy
Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017) · BioDrugs · doi:10.1007/s40259-017-0234-5 · Cited by 1,362
“(SPK-9001, SPK-8011), Sangamo Therapeutics (SB-525), UniQure (AMT-060), Dimension Therapeutics (DTX101, DTX201), and Biomarin (BMN 270) (Table 3) [97].”
BackgroundMethodGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.